
Sign up to save your podcasts
Or


Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937
By BMJ Group4.2
99 ratings
Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937

506 Listeners

35 Listeners

49 Listeners

298 Listeners

4 Listeners

9 Listeners

6 Listeners

3 Listeners

2 Listeners

3 Listeners

27 Listeners

41 Listeners

14 Listeners

1 Listeners

50 Listeners

0 Listeners

6 Listeners

15 Listeners

3 Listeners

26 Listeners

23 Listeners

135 Listeners

1,183 Listeners

84 Listeners

0 Listeners